Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
parsaclisib + pembrolizumab
- Development stage
- Discontinued
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Combination of parsaclisib, a highly selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, and pembrolizumab, a programmed death-1 (PD-1) inhibitor monoclonal antibody. This combination was investigated in patients with advanced or metastatic solid tumors who had disease progression following all available therapies. The rationale for combining these agents was to enhance antitumor immune responses by targeting both the PI3Kδ pathway in immune cells and the PD-1/PD-L1 checkpoint axis. The combination showed modest clinical activity but did not demonstrate sufficient efficacy to support continued development for solid tumors[2][1].
- Brand names
- Keytruda
- Other names
- MK-3475MK3475MK 3475SCH 900475SCH900475SCH-900475PI3K-delta inhibitor INCB050465PI-3K-delta inhibitor INCB050465PI 3K-delta inhibitor INCB050465
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on parsaclisib + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on parsaclisib + pembrolizumab.